



former	 element	 predominant,	 most	 commonly	 found	 in	 the	
uterine	corpus	(1-4).
In	1916,	Lopstein	first	described	a	lipoleiomyoma,	but	this	
received	 little	 attention	 in	 the	 literature	 (5).	 Its	 lack	of	 spe-
cific	histological	features	led	researchers	to	underestimate	its	




designated	 these	 tumors	 as	 “uterine	 fatty	 tumors”	 and	 sub-
divided	them	into	“lipoma”	and	“mixed	lipoma/leiomyoma”	
(lipoleiomyoma).	Modern	research	rejects	the	view	that	these	
tumors	 are	 hamartomas,	 choristomas,	 fatty	 metamorphosis,	
































were	 in	 the	cervix.	One	broad	ligament	 tumor	and	one	retroperito-
neal	tumor	were	also	studied.	No	tumors	displayed	cytologic	atypia,	









Conclusion:	 In	 the	 present	 study,	 the	 lipoleiomyomas	 were	 seen	
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(January	2000	-	April	2013).	Seventy	patients	showed	76	lipo-
leiomyomas	in	the	Department	of	Pathology.












endometrial	 hyperplasia,	 endometrial	 polyp,	 endometriosis,	
adenomyosis,	atypia	of	smooth	muscle	cells,	atypia	of	adipo-
cytes,	 necrosis,	mitosis,	 lymphocytic	 infiltration,	 and	 tumor	
borders	(circumscribed	versus	infiltrative).	The	presence	and	
amount	of	 adipocytes	was	graded	using	a	 three	 tier	grading	








formalin-fixed,	 paraffin-embedded	 representative	 tissue	 sec-










for	Windows,	 version	 17	 (SPSS,	 Chicago,	 IL,	 USA).	With	
the	Spearman	correlation	and	chi-square	analysis,	we	 tested	
for	 correlations	 of	 lipoleiomyomas	 with	 various	 pathologic	
and	 clinical	 features,	 including	 age,	 carcinoma,	 endometrial	




From	2000	 to	 2013,	 the	 Pathology	Department’s	 files	 in-
cluded	 70	 patients	with	 76	 uterine	 lipoleiomyomas.	During	
the	same	duration,	2600	uterine	leiomyomas	were	seen,	thus	









cedures:	 62	 (88.5%)	 underwent	 hysterectomy	 and	 bilateral	
salpingo-oophorectomy,	while	eight	(11.4%)	underwent	myo-
mectomy.	The	majority	of	lipoleiomyomas	were	in	the	uterine	
corpus	 (69	 cases,	 90.7%),	 but	 some	were	 found	 in	 the	 cer-
vix	(5	cases,	6.5%).	Another	was	retroperitoneal	and	one	was	
located	 in	 the	broad	 ligament	 (1.3%).	Fifty-eight	 tumors	af-
fected	the	uterine	corpus,	and	were	intramural,	two	were	sub-




in	diameter,	with	 a	mean	of	5.50	 cm.	All	were	nodular	 and	





II	 (moderate)	 in	 3	 (3.9%)	 and	grade	 III	 (abundant,	multifo-
cal	and	evenly	distributed	throughout	the	tumor)	in	38	(50%)	
lipoleiomyomas.	









Antibody	 Clone	 Dilution	 Manufacturer
Desmin	 D33	 1/50	 Thermo
Vimentin	 V9	 Ready	to	use	 Dako
SMA	 1A4	 Ready	to	use	 Dako
S100	 Polyclonal	 Ready	to	use	 Dako
HMB-45	 HMB-45	 Ready	to	use	 Dako
Ki-67	 SP6	 1/200	 Thermo
ER	 EP1	 Ready	to	use	 Dako
PR	 PgR636	 Ready	to	use	 Dako
SMA:	smooth	muscle	actin;	ER:	estrogen;	PR:	progesterone
TABLE 1. Antibodies	used
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In	all	70	patients,	we	found	12	cases	(17.1%)	of	gynecolog-















In	 the	 immunohistochemical	 investigation,	we	 studied	 the	
expression	of	ER	and	PR	receptors,	Ki-67,	SMA,	HMB-45,	
















Uterine	 lipoleiomyoma	is	a	 rare	and	specific	 type	of	 leio-
myoma	with	a	considerable	amount	of	adipocytes	(1-3).	The	
clinical	features	and	histogenesis	of	this	tumor	continue	to	be	
uncertain.	 In	most	of	our	patients,	 lipoleiomyoma	was	 inci-
dentally	found	during	surgery	for	other	reasons.	As	observed	
in	 previous	 studies,	 lipoleiomyoma	 most	 commonly	 grows	
in	 the	 uterine	 corpus	 at	 the	 subserosal	 or	 intramural	 levels	
FIG. 1. Gross image of a lipoleiomyoma with a high adipocyte 
component, showing a well-circumscribed soft mass with a yellow cut 






















FIG. 2. a, b. Microscopic examination of a lipoleiomyoma with a high 
adipocyte component (H&E, 40×). The adipose tissue is positive for 
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study;	 a	 slightly	 lower	 incidence	 (0.03%	 to	2.1%)	has	been	
reported	 in	 the	 literature	(1,	2,	5,	9).	This	may	be	related	 to	
the	extensive	sampling	of	all	leiomyomatous	nodules.	Many	
lipoleiomyomas	 ranged	 from	 0.5	 to	 2	 cm	 in	 the	 study.	The	
clinical	presentation	of	uterine	lipoleiomyomas	is	non-specif-
ic,	and	 these	 tumors	generally	occur	 in	asymptomatic	obese	
perimenopausal	 or	 menopausal	 women	 (1,	 2,	 6).	 The	 most	
common	signs	and	symptoms	are	abnormal	uterine	bleeding,	
abdominal	 and/or	 pelvic	 pain,	 a	 palpable	mass,	 urinary	 fre-
quency,	 incontinence	 and	 a	 sensation	 of	 pressure	 similar	 to	
those	of	typical	leiomyomas	(1,	2).	Although	most	leiomyo-
mas	tend	to	predominate	in	women	of	reproductive	age,	lipo-















cells	accompanying	 the	blood	vessels	 into	 the	uterus,	 inclu-





munohistochemical	 studies	 have	 indicated	 a	 complex	 histo-
genesis	 of	 lipoleiomyoma	which	might	 arise	 from	multipo-
tential	undifferentiated	mesenchymal	cells	(15)	or	from	direct	
transformation	of	 smooth	muscle	 cells	 into	 adipocytes	 (16).	
Aung	 et	 al.	 (2)	 and	Terada	 show	 focal	 proliferation	 of	 adi-






desmin,	vimentin,	 and	ER	and	PR	 receptors,	 supporting	 the	
direct	 transformation	 of	muscle	 cells	 into	 adipose	 cells	 that	
may	originate	from	the	transformation	of	a	totipotent	mesen-
chymal	cell	(3,	17).
Uterine	 smooth	 muscle	 cells	 have	 divergent	 differentia-





plastic	 process.	 Many	 authors	 have	 performed	 cytogenetic	
studies	 of	 uterine	 lipoleiomyomas,	 and	 suggest	 that	 uterine	








may	 play	 a	 role	 in	 lipoleiomyoma	 development.	Adipocyte	
differentiation	 in	 the	myometrium	has	 been	 observed	 under	
conditions	 such	 as	 toxemia	during	pregnancy	 (20),	 so	 envi-
ronmental	factors	in	the	uterus	may	play	a	role	in	adipocyte	
differentiation	 in	 lipoleiomyomas	 (18,	 20).	The	 relationship	
between	 gynecologic	 malignancies,	 which	 may	 originate	




FIG 3. a-c. Lipoleiomyoma consisting of mature smooth muscle cells and adipose tissue positive for S100 protein (immunostaining 100x) (a). The 
adipose tissue is positive for Ki-67 (short arrow, immunostaining 400x) (b). The smooth muscle cells and adipose tissue are positive for estrogen 
receptors (immunostaining, 200x) (c)
a b c
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10	cases	(20%)	of	patients	with	uterine	lipoleiomyoma	associ-
ated	with	 gynecologic	malignancies.	 In	 our	 70	 patients,	we	












Recognition	of	 this	 rare	and	benign	 tumor	 is	of	great	 im-
portance,	because	it	may	be	confused	with	other	gynecologic	
maladies,	 including	 spindle	 cell	 lipoma,	 angiolipoma,	 an-
giomyolipoma,	 atypical	 lipoma,	myelolipoma,	myxoid	mes-
enchymal	 tumors,	 pelvic	 fibromatosis,	 well-differentiated	
liposarcoma,	 carcinosarcoma	 (malignant	 mixed	 Müllerian	
tumor)	 with	 heterologous	 liposarcomatous	 differentiation,	

























In	 conclusion,	 uterine	 lipoleiomyomas	 are	 benign	 uterine	
lesions	 that,	 in	 the	present	study,	accounted	for	2.9%	of	be-
nign	uterine	 leiomyomas.	We	conclude	that	uterine	 lipoleio-
myomas	represent	a	variant	of	leiomyoma	with	adipocyte	dif-
ferentiation	 rather	 than	 a	 degenerative	 or	 neoplastic	 change	
in	 ordinary	 leiomyoma.	 Patients	 with	 lipoleiomyomas	 have	
many	 estrogen-related	 conditions	 including	 endometriosis,	
adenomyosis,	 endometrial	 hyperplasia,	 polyps,	 and	 gyne-
cologic	malignancies.	 In	 this	 study,	 based	 on	 the	 follow-up	
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